Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Intervalo de año de publicación
1.
Ghana Med J ; 57(3): 175-182, 2023 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-38957678

RESUMEN

Objective: To describe the clinical characteristics and identifiable risk factors for Chronic Obstructive Pulmonary Disease (COPD) in a real-world clinical setting. Design: Cross-sectional study among patients with COPD. Setting: The Respiratory clinic of the Lagos University Teaching Hospital. Participants: Consecutive patients with spirometry confirmed COPD on follow-up for ≥3 months. There were 79 participants. Intervention: None. Main outcome measure: COPD risk factors, disease severity, comorbidities, and the severity of airflow limitation. Results: The mean age of the participants was 63.3± 12.4 years, and 47 (59.5) were male. There was a high symptom burden (73.4% had COPD assessment test (CAT) score >10), 33 (41.8%) and 4 (5.1%) had GOLD 3 and GOLD 4 airflow limitation, respectively. Risk factors were identified for 96.2% of the participants: history of asthma in 37 (46.8%), tobacco smoking 22 (27.8%), occupational exposure 15 (19%), biomass exposure 5 (6.6%), post-tuberculosis 3 (3.8%), old age (3.8%), and prematurity 1 (1.3%). Fifty-nine (74.7%) had Asthma COPD Overlap (ACO). There were no significant associations between the risk factors and disease severity. Participants with ACO had lower lung function and a high frequency of allergic rhinitis. Conclusion: Asthma was the most commonly identifiable risk factor for COPD, underscoring asthma risk reduction and management optimisation as priorities toward COPD burden mitigation. Future studies need to validate these findings and identify the predominant COPD phenotypes in our setting. Funding: None declared.


Asunto(s)
Enfermedad Pulmonar Obstructiva Crónica , Índice de Severidad de la Enfermedad , Espirometría , Humanos , Enfermedad Pulmonar Obstructiva Crónica/epidemiología , Masculino , Nigeria/epidemiología , Femenino , Factores de Riesgo , Estudios Transversales , Persona de Mediana Edad , Anciano , Asma/epidemiología , Centros de Atención Terciaria , Comorbilidad , Exposición Profesional/efectos adversos
2.
Ghana Med. J. (Online) ; 57(3): 175-182, 2023.
Artículo en Inglés | AIM (África) | ID: biblio-1517564

RESUMEN

Objective: To describe the clinical characteristics and identifiable risk factors for Chronic Obstructive Pulmonary Disease (COPD) in a real-world clinical setting. Design: Cross-sectional study among patients with COPD. Setting: The Respiratory clinic of the Lagos University Teaching Hospital. Participants: Consecutive patients with spirometry confirmed COPD on follow-up for ≥3 months. There were 79 participants. Intervention: None Main outcome measure: COPD risk factors, disease severity, comorbidities, and the severity of airflow limitation. Results: The mean age of the participants was 63.3± 12.4 years, and 47 (59.5) were male. There was a high symptom burden (73.4% had COPD assessment test (CAT) score >10), 33 (41.8%) and 4 (5.1%) had GOLD 3 and GOLD 4 airflow limitation, respectively. Risk factors were identified for 96.2% of the participants: history of asthma in 37 (46.8%), tobacco smoking 22 (27.8%), occupational exposure 15 (19%), biomass exposure 5 (6.6%), post-tuberculosis 3 (3.8%), old age (3.8%), and prematurity 1 (1.3%). Fifty-nine (74.7%) had Asthma COPD Overlap (ACO). There were no significant associations between the risk factors and disease severity. Participants with ACO had lower lung function and a high frequency of allergic rhinitis. Conclusion: Asthma was the most commonly identifiable risk factor for COPD, underscoring asthma risk reduction and management optimisation as priorities toward COPD burden mitigation. Future studies need to validate these findings and identify the predominant COPD phenotypes in our setting.


Asunto(s)
Comorbilidad , Factores de Riesgo , Exposición Profesional , Enfermedad Pulmonar Obstructiva Crónica , Asma
3.
Microbiol Spectr ; 10(4): e0036622, 2022 08 31.
Artículo en Inglés | MEDLINE | ID: mdl-35913205

RESUMEN

The dynamics of Lassa virus (LASV) infections in rodent reservoirs and their endemic human caseloads remain poorly understood. During the endemic period, human infections are believed to be associated with the seasonal migration of Mastomys natalensis, thought to be the primary reservoir that triggers multiple spillovers of LASV to humans. It has become imperative to improve LASV diagnosis in rodents while updating their prevalence in two regions of Lassa fever endemicity in Nigeria. Rodents (total, 942) were trapped in Ondo (531) and Ebonyi (411) states between October 2018 and April 2020 for detection of LASV using various tissues. Overall, the LASV prevalence was 53.6%. The outbreak area sampled in Ondo had three and two times higher capture success and LASV prevalence, respectively, than Ebonyi State. This correlated with the higher number of annual cases of Lassa fever (LF) in Ondo State versus Ebonyi State. All rodent genera (Mastomys, Rattus, Crocidura, Mus, and Tatera) captured in both states showed slightly variable LASV positivity, with Rattus spp. being the most predominantly infected (77.3%) rodents in Ondo State versus Mastomys spp. (41.6%) in Ebonyi State. The tissues with the highest LASV positivity were the kidneys, spleen, and testes. The finding of a relatively high LASV prevalence in all of the rodent genera captured highlights the complex interspecies transmission dynamics of LASV infections in the reservoirs and their potential association with increased environmental contact, as well as the risk of zoonotic spillover in these communities, which have the highest prevalence of Lassa fever in Nigeria. IMPORTANCE Our findings show the highest LASV positivity in small rodents ever recorded and the first direct detection of LASV in Tatera spp. Our findings also indicate the abundance of LASV-infected small rodents in houses, with probable interspecies transmission through vertical and horizontal coitus routes. Consequently, we suggest that the abundance of different reservoir species for LASV may fuel the epizootic outbreaks of LF in affected human communities. The high prevalence of LASV with the diversity of affected rodents has direct implications for our understanding of the transmission risk, mitigation, and ultimately, the prevention of LF in humans. Optimal tissues for LASV detection in rodents are also presented.


Asunto(s)
Epidemias , Fiebre de Lassa , Animales , Humanos , Fiebre de Lassa/epidemiología , Fiebre de Lassa/prevención & control , Fiebre de Lassa/veterinaria , Virus Lassa , Murinae , Nigeria/epidemiología , Prevalencia , Ratas
4.
Trop Med Int Health ; 26(1): 54-65, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-32985028

RESUMEN

OBJECTIVE(S): To determine the availability and affordability of asthma and COPD medicines across Nigeria. METHODS: This was a cross-sectional survey conducted in 128 pharmacies (51 in public sector hospitals, 51 private sector community pharmacies and 26 charity or big private hospitals) across the six geopolitical zones of Nigeria using the WHO/Health Action Initiative method. The proportion of pharmacies where medicines were available, the median retail prices of originator and generics and affordability were analysed. A medicine was available if found in ≥ 80% of surveyed pharmacies. Unaffordability was defined as paying> 1 day's wage (> US$1.68) for a standard 30-day supply of the medicine. RESULTS: The available medicines were oral corticosteroids and oral salbutamol which are not on the WHO Essential Medicine List. Medicines were found more frequently in private than public pharmacies and in the southern than northern zones. Inhalable corticosteroid was not available at any public pharmacy nationwide. None of the EML medicines were affordable. The least number of days' wages for a 30-day supply of any inhalable corticosteroid-containing medication was 3.5 days. CONCLUSIONS: There are very limited availability and affordability of recommended asthma and COPD medicines across Nigeria with disparity across regions. Medicines that were available and affordable are not recommended and are harmful for long-term use. This underpins the need for engagement of all stakeholders for the review of existing policies regarding access to asthma and COPD medicines to improve availability and affordability.


Asunto(s)
Asma/economía , Costos y Análisis de Costo/economía , Medicamentos Esenciales/economía , Medicamentos Esenciales/provisión & distribución , Accesibilidad a los Servicios de Salud/economía , Enfermedad Pulmonar Obstructiva Crónica/economía , Asma/tratamiento farmacológico , Estudios Transversales , Medicamentos Genéricos/economía , Humanos , Nigeria , Sector Privado/economía , Sector Público/economía , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Encuestas y Cuestionarios , Organización Mundial de la Salud
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...